Company intelligence / Profile preview

Fera Pharmaceuticals

Locust Valley, New York, United Statesferagb.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Fera Pharmaceuticals is a specialty pharmaceutical company focused on preserving and expanding treatment options for patients with unmet needs, particularly in ophthalmology and orphan/niche indications. Its lead product is phospholine iodide for glaucoma. The company has acquired assets such as an abandoned pediatric glaucoma drug from Pfizer to expand its portfolio. It emphasizes maintaining access to essential medicines that might otherwise disappear from the market.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

2 assets

Puralube

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Not specifically listed; open to licensing/product development partnerships.

Beyond the preview

Go deeper on Fera Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fera Pharmaceuticals.

Explore the full profile